AIM
FRTX

Alambic Investment Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Alambic Investment Management’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-308
Closed -$141K – 474
2018
Q1 		$141K Sell
308
-63
-17% -$31.3K 0.02% 425
2017
Q4 		$214K Buy
+371
New +$244K 0.03% 406

Other funds holding FRTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alambic Investment Management's FRTX Position: Q2 2018 in Review

Alambic Investment Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2018, closing a stake of 308 shares — an estimated $141K sold.

Alambic Investment Management first reported a position in FRTX in Q4 2017 and held it in 2 quarters. The position peaked at $214K in Q4 2017. 28 funds tracked by Wall St. Rank hold FRTX as of Q2 2018.

  • Alambic Investment Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Alambic Investment Management sold 308 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $141K.
  • Alambic Investment Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Alambic Investment Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $214K in Q4 2017.
  • 28 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Alambic Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.